AADI News and Press, Aadi Bioscience Inc. From 08/10/22

Aadi Bioscience, Inc. (AADI) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer ...

Aadi Bioscience press release ( NASDAQ: AADI ): Q2 GAAP EPS of -$0.87. Revenue of $3.43M. Cash and cash equivalents on June 30, 2022 were $118.7 million, compared to $149.0 million as of December 31, 2021. Based on current plans, the Company expects cash and cash equiv...

Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update PR Newswire FYARRO ® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 PRECISION 1 Phase 2 tumor-agnostic r...

Major earnings expected before the bell on Wednesday include: Ballard Power Systems ( BLDP ) Jumia Technologies ( JMIA ) Paysafe ( PSFE ) Trulieve Cannabis ( OTCQX:TCNNF ) Wix.com ( WIX ) For further details see: Notable earnings before We...

Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on August 10 LOS ANGELES , July 28, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutic...

Aadi Bioscience, Inc. (AADI) Q1 2022 Earnings Conference Call May 12, 2022, 08:30 ET Company Participants Andrew Quan - VP, Business Development & Corporate Strategy Neil Desai - Founder, President, CEO, Secretary & Director Brendan Delaney - COO Loretta Itri - Chief Medical Officer S...

FYARRO net product sales of $2.3 million in partial first quarter Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors Conference call to be held today at 8:30...

Aadi Bioscience press release (NASDAQ:AADI): Q1 GAAP EPS of -$0.66. Revenue of $2.31M (+1825.0% Y/Y). As of March 31, 2022, cash and cash equivalents totaled $129.8 million, compared to $149.0 million as of December 31, 2021. Based on our current plans, we expect cash and cash equivalents to ...

FYARRO net product sales of $2.3 million in partial first quarter Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors LOS ANGELES, May 12, 2022 (GLOBE NEWSWIR...

AADI,ACHR,ACTG,ADN,AEG,OTCPK:ALIZF,ALT,AMTX,OTCPK:ARNGF,ARQQ,ATY,BAM,BGRY,BKKT,BT,CAMT,CASI,CORR,CPG,CYBR,CYXT,DAVA,DCBO,DRIO,EMAN,EURN,GENI,HIMX,OTCPK:HNHAF,HUT,IS,KNOP,KT,LQDA,MGIC,OTCPK:MKGAF,ML,MOGO,MTNB,NETI,NICE,OTCPK:NSANY,NVMI,ORTX,PCT,OTCPK:PEYUF,OTCQX:QTRHF,RDCM,OTCPK:RWEOY,SCYX,SFL...